[1]Patel YA, Muir AJ. Evaluation of new-onset ascites. JAMA, 2016, 316(3): 340-341. [2]Akiyama S, Ikeda K, Sezaki H, et al. Therapeutic effects of short and intermediate term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis. Hepatol Res, 2016, 45(11): 1062-1070. [3]Jia JD, Xie W, Ding HG, et al. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: a prospective cohort study. Ann Hepatol, 2017, 16(1): 123-132.[4]Wong F. Acute kidney injury in liver cirrhosis: new definition and application. Clin Mol Hepatol, 2016, 22(4): 415-422. [5]Xia Y, Li J, Li S, et al. Clinical value of urinary retinol-binding protein in ascites due to cirrhosis. Exp Ther Med, 2017, 14(5): 5228-5234. [6]中华医学会肝病学分会、消化病学分会、内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 实用肝脏病杂志,2016,19(5):Ⅰ-ⅩⅤⅠ. [7]Facciorusso A, Roy S, Livadas S, et al. Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites. Dig Dis Sci, 2018, 63(7): 1737-1746. [8]Smith M, Durham J. Evolving indications for tips. Techvasc Interv Radiol, 2016, 19(1): 36-41. [9]Gonzalez-Calero L, Martinlo-Renzo M, Ramos-Barron A, et al. Urinary kininogen-1 and retinol binding protein-4 respond to acute kidney injury: predictors of patient prognosis. Sci Rep, 2016, 6(1): 19667. [10] Yuan Y, Wang C, Shao X, et al. Urinary retinol-binding protein as a risk factor of poor prognosis in acute-on-chronic renal injury. J Nephrol, 2016, 29(6): 827-833. [11] Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology, 2015, 62(2): 567-574. [12] Parikh A, Rizzo JA, Canetta P, et al. Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis. Plos One, 2017, 12(5):e0178091. [13] 田秋菊,贾继东.失代偿期肝硬化及其相关并发症治疗新进展. 实用肝脏病杂志, 2015, 18(1): 1-3. [14] Zelnick LR, Katz R, Young BA, et al. Echocardiographic measures and estimated GFR decline among African Americans: the jackson heart study. Am J Kidney Dis, 2017, 70(2): 199-206. [15] 花兴萍, 朱蔚岗, 刘明水. 细菌感染诱发乙型肝炎肝硬化患者发生肝性脑病60例回顾性研究. 实用肝脏病杂志, 2017, 20(3): 358-359. [16] Woo LS, Ha BS, Young AS, et al. Theeffects of pre-existing hyponatremia and subsequent-developing acute kidney injury on in-hospital mortality: a retrospective cohort study. Plos One, 2016, 11(9): e0162990. [17] Tamme K, Oselin K, Kipper K, et al. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock. Acta Anaesthesiol Scand, 2016, 60(2): 230-240. [18] Tergast TL, Wranke A, Laser H, et al. Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver Int, 2018, 38(9): 1602-1613. [19] Lahmer T, Brandl A, Rasch S, et al. Fungal peritonitis: underestimated disease in critically ill patients with liver cirrhosis and spontaneous peritonitis. Plos One, 2016, 11(7): e0158389. [20] Li KT, Burdmann EA, Mehta RL. Acute kidney injury: acute kidney injury-global health alert. Nat Rev Nephrol, 2013, 9(3): 133-135. |